Skip to main content
. 2011 Oct 17;102(12):2191–2198. doi: 10.1111/j.1349-7006.2011.02100.x

Figure 1.

Figure 1

 (A) Hierarchical clustering of differentially expressed genes evaluated by oligonucleotide microarray according to patient outcome. The locations of genes in the MMP, TIMP, and IMP families are indicated. A, MYCN amplified; D, differentiating neuroblastoma; G, ganglioneuroblastoma; m, months; N, MYCN not amplified; U, undifferentiated neuroblastoma. (B) Mean IMP3 expression levels with 95% confidence intervals evaluated by oligonucleotide microarray showing that neuroblastoma patients with poor prognosis, defined as dead or disease relapse within 3 years, had significantly higher IMP3 expression levels in tumor tissues than those with good prognosis, defined as disease‐free survival >3 years (P = 0.015, upper panel). The result was reconfirmed in the same 22 patients by quantitative real‐time PCR (P = 0.013, lower panel). (C) Mean IMP3 expression levels with 95% confidence intervals evaluated by oligonucleotide microarray showing that the IMP3 expression level was significantly higher in neuroblastoma tumors with MYCN amplification (n = 10) than in tumors without MYCN amplification (n = 12, P = 0.001, upper panel). The results were confirmed by PCR analysis in the same 22 patients (P = 0.003, lower panel).